Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Summary

The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.

Timeline

Start

2025-03-31

Primary completion

2027-01

Completion

2027-04

Drugs

Indications